Acellular Dermal Allograft for Chronic Diabetic Wounds (NCT06227520)
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the efficacy of a novel decellularized dermal matrix (DDM) DermGENβ’ for the treatment of diabetic foot ulcers (DFU). Despite several advances in wound treatments, hard-to-heal wounds, such as diabetic foot ulcer, still require 12 to 16 weeks to achieve complete closure. Although the focus of most research into wound-healing treatments has been on moisture and bacterial control, new approaches that target the instability of the extracellular matrix (ECM) in a wound are timely and much needed, particularly for hard-to-heal wounds such as DFUs. Innovative technologies that provide ECM interactions halt the chronic inflammatory cycle and stimulate cells that allow for tissue regeneration and wound healing. DermGENβ’ is a human dermal allograft that has been minimally processed from human skin to remove epidermal and dermal cells while preserving the structure and intrinsic properties of the natural extracellular matrix of the dermis. This has potential to facilitate a shorter wound-healing time.
Who can join: Review the eligibility criteria below.
Location: University Health Network β Toronto, Ontario
Age range: 18 Years
π§ͺ Interventions in This Study
- decellularized dermal matrix (OTHER)
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- University Health Network β Toronto, Ontario
π Contact the Study Coordinator
Phone: (416) 340-5332
Email: Graham.Roche-Nagle@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Wound Heal
- Dermabrasion in Mohs: Split-Scar Trial β Madison, Wisconsin
- Amnion Membrane Powder Mohs Study β Winston-Salem, North Carolina
- Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds β Washington D.C., District of Columbia
- IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers β Fresno, California
- EDX110 Randomized Control Trial for Treatment of DFUs β Phoenix, Arizona
Explore by condition: All Wound Heal clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.